about cadrenal
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, which is designed to be a superior and safer Vitamin K antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular conditions. Cadrenal strives to improve outcomes and reduce major events for these patients, who lack chronic anticoagulation options besides warfarin, well-known for its serious side effects, and cumbersome treatment management. The company aims to relieve patients and their healthcare providers from some of warfarin’s greatest challenges.
The company’s Phase 3-ready drug candidate, tecarfarin, is a new VKA chronic anticoagulant with extensive data showing its potential to be superior to warfarin, resulting in fewer adverse events such as strokes, heart attacks, bleeds and deaths. Tecarfarin received an orphan drug designation for heart failure patients with left ventricular assist devices (LVADs) as well as both orphan drug and fast track status for end-stage kidney disease (ESKD) patients with atrial fibrillation (Afib). Cadrenal is opportunistically pursuing pivotal clinical trials along with clinical and commercial partnership opportunities. The company’s plans also include studying patients with mechanical heart valves experiencing anticoagulation difficulties because of genetic warfarin resistance, polypharmacy, or kidney impairment.
Tecarfarin is metabolized via a different pathway than warfarin and data shows that its efficacy is unaffected by common drug-drug interactions or kidney impairment, which are common in these patients. Phase 2/3 clinical trials show that tecarfarin may offer more stability and time in therapeutic range that inversely correlates with major events.
With the only new VKA blood thinner being developed for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions, Cadrenal is boldly challenging the status quo to innovate a new anticoagulant providing better care for underserved patients.
PRESS RELEASES
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
PONTE VEDRA, Fla., Nov. 7, 2024 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the “Company” or “Cadrenal”), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
PONTE VEDRA, Fla., Nov. 1, 2024 — Cadrenal Therapeutics, Inc., (“Cadrenal” or the “Company”) (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
PONTE VEDRA, Fla., Oct. 24, 2024 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the “Company” or “Cadrenal”), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin
Events
INVESTOR CONTACTS
COMPANY CONTACT
Cadrenal Therapeutics, Inc.
Matthew Szot, CFO
Phone: 904.300.0701
Email: [email protected]
INVESTOR RELATIONS CONTACT
Lytham Partners, LLC
Robert Blum
Phone: 602.889.9700
Email: [email protected]
TRANSFER AGENT
Transfer Online, Inc.
512 SE Salmon St.
Portland, OR 97214
Phone: 503.227.2950
Email: [email protected]